CD4+ T cell responses in patients with chronic hepatitis C undergoing peginterferon/ribavirin therapy correlate with faster, but not sustained, viral clearance

Journal of Infectious Diseases

Volumn 195, Issue 9, 2007, Pages 1315-1319

  Aberle, Judith H ^a   Perstinger, Gabriela ^a   Weseslindtner, Lukas ^a   Sinzinger, Ursula ^a   Gurguta, Calin ^b   Steindl Munda, Petra ^b   Kundi, Michael ^b   Popow Kraupp, Theresia ^a   Ferenci, Peter ^b   Holzmann, Heidemarie ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HEPATITIS C ANTIGEN; NONSTRUCTURAL PROTEIN 3; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CHRONIC HEPATITIS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; FEMALE; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; TH1 CELL; TREATMENT OUTCOME; VIREMIA; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 34247466933     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/513278     Document Type: Article

References (16)

1. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005; 5:215-9.
2. Moradpour D. Hepatology highlights: viral hepatitis. Hepatol 2004; 40:4-5.
3. Missale G, Cariani E, Ferrari C. Role of viral and host factors in HCV persistence: which lesson for therapeutic and preventive strategies? Dig Liver Dis 2004; 36:703-11.
4. Kaplan DE, Sugimoto K, Ikeda F, et al. T-cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C. Hepatol 2005; 41:1365-75.
5. + T-helper 1 responses in patients with chronic hepatitis C. Gastroenterol 2002; 123:1070-83.
6. Barnes E, Harcourt G, Brown D, et al. The dynamics of T-lymphocyte responses during combination therapy for chronic hepatitis C virus infection. Hepatol 2002; 36:743-54.
7. + T-cell responses in acute hepatitis C virus infection and early therapy. J Virol 2005; 79:12979-88.
8. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
9. Herrmann E, Neumann AU, Schmidt JM, Zeuzem S. Hepatitis C virus kinetics. Antivir Ther 2000; 5:85-90.
10. Ferenci P, Bergholz U, Laferl H, et al. 24 week treatment regimen with peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) in HCV genotype 1 or 4 'superresponders' [abstract 8]. Abstracts of the 41st Annual Meeting of the European Association for the Study of the Liver. J Hepatol 2006; 44(Suppl):S6.
11. Ferenci P, Brunner H, Laferl H, et al. Further reduction of ribavirin dose in HCV genotype 2/3 patients receiving peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®): interim results of a randomized controlled trial [abstract 82]. Abstracts of the 41st Annual Meeting of the European Association for the Study of the Liver. J Hepatol 2006; 44(Suppl):S37.
12. + T cell response in acute hepatitis C primary infection and reinfection. J Clin Virol 2006; 36:24-31.
13. Hultgren C, Desombere I, Leroux-Roels G, et al. Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses. J Hepatol 2004; 40:971-8.
14. Tang KH, Herrmann E, Cooksley H, et al. Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. J Viral Hepatol 2005; 43:776-82.
15. Ferenci P, Fried MW, Shiffman ML, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a/ribavirin. J Hepatol 2005; 43:425-33.
16. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy. Hepatol 2006; 43:954-60.